发明授权
US07544678B2 Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
失效
针对雷诺地尔受体(RyR2)泄漏的抗心律失常药物和心力衰竭药物
- 专利标题: Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
- 专利标题(中): 针对雷诺地尔受体(RyR2)泄漏的抗心律失常药物和心力衰竭药物
-
申请号: US11088058申请日: 2005-03-23
-
公开(公告)号: US07544678B2公开(公告)日: 2009-06-09
- 发明人: Andrew Robert Marks , Donald W. Landry , Shixian Deng , Zhen Zhuang Cheng
- 申请人: Andrew Robert Marks , Donald W. Landry , Shixian Deng , Zhen Zhuang Cheng
- 申请人地址: US NY New York
- 专利权人: The Trustees of Columbia University In the City of New York
- 当前专利权人: The Trustees of Columbia University In the City of New York
- 当前专利权人地址: US NY New York
- 代理机构: Wilmer Cutler Pickering Hale and Dorr LLP
- 主分类号: A61P9/00
- IPC分类号: A61P9/00 ; A61K31/553 ; A61K31/554 ; A61K31/675 ; C07F9/553 ; C07D281/02
摘要:
The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.
公开/授权文献
信息查询